353 related articles for article (PubMed ID: 26529068)
21. Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine.
Dragunsky EM; Ivanov AP; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
J Infect Dis; 2006 Sep; 194(6):804-7. PubMed ID: 16941347
[TBL] [Abstract][Full Text] [Related]
22. Universal ELISA for quantification of D-antigen in inactivated poliovirus vaccines.
Kouiavskaia D; Puligedda RD; Dessain SK; Chumakov K
J Virol Methods; 2020 Feb; 276():113785. PubMed ID: 31765719
[TBL] [Abstract][Full Text] [Related]
23. Engineering Enhanced Vaccine Cell Lines To Eradicate Vaccine-Preventable Diseases: the Polio End Game.
van der Sanden SM; Wu W; Dybdahl-Sissoko N; Weldon WC; Brooks P; O'Donnell J; Jones LP; Brown C; Tompkins SM; Oberste MS; Karpilow J; Tripp RA
J Virol; 2016 Feb; 90(4):1694-704. PubMed ID: 26581994
[TBL] [Abstract][Full Text] [Related]
24. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants.
Verdijk P; Rots NY; van Oijen MG; Weldon WC; Oberste MS; Okayasu H; Sutter RW; Bakker WA
Vaccine; 2014 Sep; 32(39):4938-44. PubMed ID: 25043278
[TBL] [Abstract][Full Text] [Related]
25. Rapid and accurate identification of poliovirus strains used for vaccine production.
Nijst OE; Mouthaan JJ; Mekkes DR; Jusic E; van der Avoort HG; Metz B
J Virol Methods; 2013 Apr; 189(1):189-95. PubMed ID: 23434540
[TBL] [Abstract][Full Text] [Related]
26. A novel gamma radiation-inactivated sabin-based polio vaccine.
Tobin GJ; Tobin JK; Gaidamakova EK; Wiggins TJ; Bushnell RV; Lee WM; Matrosova VY; Dollery SJ; Meeks HN; Kouiavskaia D; Chumakov K; Daly MJ
PLoS One; 2020; 15(1):e0228006. PubMed ID: 31999745
[TBL] [Abstract][Full Text] [Related]
27. sIPV process development for costs reduction.
Thomassen YE; Bakker WA
Vaccine; 2015 Aug; 33(35):4307-12. PubMed ID: 25858858
[TBL] [Abstract][Full Text] [Related]
28. Reactogenicity and immunogenicity of inactivated poliovirus vaccine produced from Sabin strains: a phase I Trial in healthy adults in Cuba.
Resik S; Tejeda A; Fonseca M; Alemañi N; Diaz M; Martinez Y; Garcia G; Okayasu H; Burton A; Bakker WA; Verdijk P; Sutter RW
Vaccine; 2014 Sep; 32(42):5399-404. PubMed ID: 25131734
[TBL] [Abstract][Full Text] [Related]
29. Dynamic profiles of neutralizing antibody responses elicited in rhesus monkeys immunized with a combined tetravalent DTaP-Sabin IPV candidate vaccine.
Sun M; Ma Y; Xu Y; Yang H; Shi L; Che Y; Liao G; Jiang S; Zhang S; Li Q
Vaccine; 2014 Feb; 32(9):1100-6. PubMed ID: 24412578
[TBL] [Abstract][Full Text] [Related]
30. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan.
Shimizu H
Vaccine; 2016 Apr; 34(16):1975-85. PubMed ID: 25448090
[TBL] [Abstract][Full Text] [Related]
31. Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication.
Macadam AJ; Ferguson G; Stone DM; Meredith J; Knowlson S; Auda G; Almond JW; Minor PD
J Virol; 2006 Sep; 80(17):8653-63. PubMed ID: 16912313
[TBL] [Abstract][Full Text] [Related]
32. Phase 3 Trial of a Sabin Strain-Based Inactivated Poliovirus Vaccine.
Liao G; Li R; Li C; Sun M; Jiang S; Li Y; Mo Z; Xia J; Xie Z; Che Y; Yang J; Yin Z; Wang J; Chu J; Cai W; Zhou J; Wang J; Li Q
J Infect Dis; 2016 Dec; 214(11):1728-1734. PubMed ID: 27658691
[TBL] [Abstract][Full Text] [Related]
33. Genetic stability and mutant selection in Sabin 2 strain of oral poliovirus vaccine grown under different cell culture conditions.
Taffs RE; Chumakov KM; Rezapkin GV; Lu Z; Douthitt M; Dragunsky EM; Levenbook IS
Virology; 1995 Jun; 209(2):366-73. PubMed ID: 7778271
[TBL] [Abstract][Full Text] [Related]
34. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.
Pliaka V; Kyriakopoulou Z; Markoulatos P
Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the genetic stability of Sabin strains and the consistency of inactivated poliomyelitis vaccine made from Sabin strains using direct deep-sequencing.
Deng Y; Cai W; Li J; Li Y; Yang X; Ma Y; Yao Y; Yang L; Shi L; Sun M
Vaccine; 2019 Jan; 37(1):130-136. PubMed ID: 30467062
[TBL] [Abstract][Full Text] [Related]
36. [Effect of 2-phenoxyethanol on potency of Sabin inactivated poliomyelitis vaccine and its safety].
Bian CX; Jiang SD; Yang JY; Sun MB; Xie MX; Zhang XW; Liao GY; Li WD
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):44-6. PubMed ID: 17429533
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the neutralizing activities of antibodies in clinical sera against both Sabin and wild-type polio pseudoviruses.
Liu S; Lu W; Ma S; Guo H; Zhang Z; Li X
J Virol Methods; 2022 Feb; 300():114376. PubMed ID: 34826519
[TBL] [Abstract][Full Text] [Related]
38. Potency of wild-type or sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site.
Sawyer LA; Wood D; Ferguson M; Crainic R; Beuvery EC; McInnis J; Albrecht P
Biologicals; 1997 Sep; 25(3):299-306. PubMed ID: 9324998
[TBL] [Abstract][Full Text] [Related]
39. Growth and poliovirus production of Vero cells on a novel microcarrier with artificial cell adhesive protein under serum-free conditions.
Kurokawa M; Sato S
J Biosci Bioeng; 2011 May; 111(5):600-4. PubMed ID: 21262586
[TBL] [Abstract][Full Text] [Related]
40. Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals.
Thomassen YE; van 't Oever AG; van Oijen MG; Wijffels RH; van der Pol LA; Bakker WA
PLoS One; 2013; 8(12):e83374. PubMed ID: 24349497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
